Stock Ratings / Health Care / PMCB / news

CRIS (40) LIMN (45) CLDI (41) CELZ (27) ⌘ Pro Terminal →

Why PMCB Stock slipped -0.78% Today — RQD Quant Desk Flash

Q: Is PMCB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, PharmaCyte Biotech Inc. (NASDAQ: PMCB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.33 (-0.78% 1D, market cap $3.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PMCB ranks #657 in composite RQD confidence.

Q: How does PMCB compare to CRIS and LIMN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PMCB carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.2%. By comparison, CRIS (Curis Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and LIMN (Liminatus Pharma Inc. (Class A)) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M). Among the 5-stock peer group, PMCB leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for PMCB?

Per PMCB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001157075), PharmaCyte Biotech Inc. generated $0 in revenue, -$19.4M in net income, and -$5.2M in free cash flow against $55.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is PMCB trading relative to its 50-day, 200-day, and 52-week technical levels?

PMCB last traded at $0.33 (-0.78% on volume of 41,128 shares), positioning the stock -21.43% below its 50-day simple moving average ($0.42) and -48.44% below its 200-day simple moving average ($0.64). Across its 52-week range of $0.30 to $1.51, PMCB sits at the 2.5% percentile with a 14-day RSI of 25.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.37).

Q: Why is PMCB stock moving today?

Why PMCB Stock slipped -0.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-30% return on capital) under elevated 10-year interest-rate pressure.

$0.33 -0.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

PharmaCyte Biotech Inc. (PMCB) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-9.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PMCB)Realized 20D OHLCV Swing Band: ±12.5%

AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why PMCB Stock slipped -0.78% Today — RQD Quant Desk Flash

PharmaCyte Biotech Inc. (PMCB) slipped -0.78% to $0.33, trading at 2% of its 52-week range ($0.3 – $1.51). Stretched risk/reward at current multiples (-30% return on capital) under elevated 10-year interest-rate pressure.

▸Technical Tape: Trading at 2% of its 52-week range ($0.3 – $1.51) with RSI-14 at 25.9 (OVERSOLD (<32)).
▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.33 (no active unusual options sweep snapshot on file).
▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.

Live PMCB Headlines & Catalysts

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PMCB)

✓Walkthrough of PMCB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PMCB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.17%⚡ TESTING RESISTANCE

2026-10-30O $0.34H $0.34L $0.30C $0.33VOL 121.7K

RES: $0.38SUP: $0.17SMA50: $0.42SMA200: $0.64

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PMCB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PMCB Butterfly Map → + Track PMCB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PMCB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PMCB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PMCB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PMCB)

Health Care Rank #657 of 1016 ⚔️ CRIS vs PMCB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PMCB vs. CRIS, LIMN, CLDI, CELZ)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, PharmaCyte Biotech Inc. (PMCB) ranks #657 by composite RQD confidence (40/100, grade D-) and #969 by equity capitalization ($3.6M). Within this direct 5-issuer industry benchmark cohort, PMCB leads on earnings valuation at N/A trailing P/E, while PMCB leads on capital efficiency and profitability with -30.2% ROIC and — gross margin. LIMN currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with PMCB at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PMCB ACTIVE PharmaCyte Biotech Inc.	D-	40/100	—	—	-30.2%	-0.78%	$3.6M	Benchmark Subject
CRIS Curis Inc.	D-	40/100	—	—	-35.0%	+20.82%	$3.7M	/cris-vs-pmcb →
LIMN Liminatus Pharma Inc. (Class A)	D	45/100	—	—	-35.0%	-0.86%	$3.9M	/limn-vs-pmcb →
CLDI Calidi Biotherapeutics Inc.	D-	41/100	—	—	-35.0%	-4.29%	$2.5M	/cldi-vs-pmcb →
CELZ Creative Medical Technology Holdings Inc.	E	27/100	—	63.4%	-35.0%	-5.78%	$5.2M	/celz-vs-pmcb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001157075

In its most recent audited fiscal period (FY2025, filed 2026-04-30), PharmaCyte Biotech Inc. (PMCB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.4M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (-73.0% YoY). On the balance sheet, PMCB closed FY2025 with $55.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-04-30	$0	-$19.4M	-$5.2M	-$5.2M	$55.9M	—
FY2024 (FY)	2025-04-30	$0	$30.7M	-$3.0M	-$3.0M	$43.8M	—
FY2023 (FY)	2024-04-30	$0	$333.8K	-$2.2M	-$2.2M	—	—

3. PMCB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PMCB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, PharmaCyte Biotech Inc. (NASDAQ: PMCB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.33 (-0.78% 1D, market cap $3.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PMCB ranks #657 in composite RQD confidence.

How does PMCB compare to CRIS and LIMN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PMCB carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.2%. By comparison, CRIS (Curis Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.7M) and LIMN (Liminatus Pharma Inc. (Class A)) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M). Among the 5-stock peer group, PMCB leads on earnings multiple (N/A) while PMCB leads on capital efficiency (-30.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PMCB?

Per PMCB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001157075), PharmaCyte Biotech Inc. generated $0 in revenue, -$19.4M in net income, and -$5.2M in free cash flow against $55.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PMCB trading relative to its 50-day, 200-day, and 52-week technical levels?

PMCB last traded at $0.33 (-0.78% on volume of 41,128 shares), positioning the stock -21.43% below its 50-day simple moving average ($0.42) and -48.44% below its 200-day simple moving average ($0.64). Across its 52-week range of $0.30 to $1.51, PMCB sits at the 2.5% percentile with a 14-day RSI of 25.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.37).

PMCB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is PMCB stock moving today?

Why PMCB Stock slipped -0.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-30% return on capital) under elevated 10-year interest-rate pressure.

Direct Sub-Reports: PMCB RQD Cockpit PMCB 12M Forecast PMCB Earnings & Move PMCB Dividends & DRIP PMCB Insiders & 13F PMCB Whale Options PMCB Profit Sankey PMCB News & Why